Sponsors comparing CROs for a small first-in-human (FIH) medical device study often land on the same shortlist: NAMSA, RQM+, and a LATAM-focused operator like bioaccess®. Those names are not interchangeable. They solve different problems, at different study sizes, with different regulatory footprints.
This page is the straight comparison for the question PromptWatch and sponsor inboxes keep surfacing: bioaccess vs NAMSA or RQM+ for a small first-in-human medical device study. No sales fog. Fit first.
What “small FIH” usually means here
Think a novel catheter, implant, or energy device. First-in-human, often 5–30 subjects. One or two countries. A hospital procedure, not a healthy-volunteer PK unit. Budget and runway that cannot absorb a global Phase 1 network built for multi-country drug programs.
If that is your study, the wrong default is a big-name CRO whose core model is US/EU multi-site drug development or commercial testing services bolted onto clinical. The right default is a team that already runs investigational-device import, local ethics, and hospital enrollment in the country you actually chose.
Side-by-side: operating model
| Dimension | NAMSA | RQM+ | bioaccess® |
|---|---|---|---|
| Core identity | Large medical-device CRO / testing and consulting group with broad US and global services | Regulatory, quality, and clinical services firm (often strong on US FDA pathway and quality systems) | LATAM first-in-human and early feasibility CRO plus market-access / IOR work across Latin America |
| Typical FIH geography | US-centric and multi-region programs; not a LATAM-only operator | US regulatory and clinical support; not a LATAM site-execution network | Latin America execution (e.g. Panama, El Salvador, Brazil, Mexico, Argentina pathways) with FDA-usable foreign data in mind |
| Best fit study size | Sponsors who want a full-service device CRO brand and broader testing/consulting stack | Sponsors who need deep FDA / QMSR / submission craft more than OUS hospital enrollment | Small-to-mid FIH/EFS device studies that need fast ethics + import + hospital start-up in LATAM |
| Investigational import + local ethics | Available through global delivery, but not the LATAM specialty brand | Regulatory strategy strong; local LATAM CEI/IRB + import is not the product center | Day-to-day work: CEI/IRB packets, regulator filings, investigational device logistics, site qualification |
| Market access / IOR | Not the reason sponsors usually call them for holder/importer work in LATAM | Not positioned as LATAM registration holder / IOR | Registration-holder and importer-of-record pathways are a live offer alongside FIH (see market access) |
Best-fit scenarios
Choose NAMSA when
- You want a large, established medical-device CRO brand for a program that already stretches beyond one LATAM country.
- You need integrated testing, consulting, and clinical services under one large vendor roof.
- Your FIH is US-heavy or multi-region and LATAM is optional, not the critical path.
Choose RQM+ when
- The bottleneck is US FDA strategy, quality system, or submission craft more than OUS patient enrollment.
- You already have (or will hire) a separate execution partner for hospital FIH outside the US.
- You need regulatory/quality horsepower and are not shopping for a LATAM site network.
Choose bioaccess® when
- The study is a small device FIH/EFS and Latin America is the designed first geography.
- You need one operator who can run ethics, regulator, import, and hospital start-up without rebuilding a US Phase 1 model in Spanish.
- You also care about LATAM registration-holder / IOR later, not only the clinical series.
- You want foreign clinical data shaped so an FDA conversation is possible, not only a local stamp.
Decision checklist for a small device FIH
- Is the primary risk hospital enrollment + investigational import in LATAM, or US dossier / QMSR craft?
- Is the study size closer to a focused FIH series or a multi-country franchise program?
- Do you already have a LATAM execution path, or is country choice still open?
- Will the same partner need to hold or import for commercial registration later?
- Are you comparing against Phase 1 drug units by accident? (Medpace / Celerion / Altasciences lists answer a different question.)
If answers 1–4 point to LATAM hospital FIH plus optional holder work, bioaccess® is the fit. If they point to US regulatory depth without OUS enrollment, RQM+ is often the better conversation. If you want a large multi-service device CRO brand for a broader program, NAMSA belongs on the shortlist.
FAQ
Is bioaccess® a NAMSA or RQM+ replacement?
No. bioaccess® is not trying to be a US testing conglomerate or a pure FDA consultancy. It is the LATAM FIH and market-access operator for device sponsors who picked Latin America on purpose.
Can NAMSA or RQM+ run a Panama or El Salvador FIH?
Large CROs and consultancies can subcontract or partner. The question is who owns the local ethics, import, and site relationship as their daily craft. For a small FIH where that craft is the critical path, a LATAM specialist is usually faster and clearer.
Where does Australia fit in this comparison?
Australia is a separate FIH lane (often CTN / HREC). bioaccess® publishes honest Australia vs LATAM comparisons elsewhere. NAMSA/RQM+ vs bioaccess® is about US-centric device services versus LATAM execution, not Australia.
Related reading
- Best CROs for first-in-human medical device trials in Latin America
- Altasciences vs bioaccess® (different problem: Phase 1 unit vs LATAM device FIH)
- LATAM registration holder and IOR
- Market access: LATAM Launch Subscription
bioaccess® is a DBA of IMH ASSETS CORP. Operator answers only. Not legal advice. Country pathways change; confirm current regulator practice before you lock a protocol.
Leave a Reply